NMN Crystal Bulk Structure for Higher Bulk Density
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nicotinamide mononucleotide (NMN) crystals have low bulk density, leading to poor fluidity and significant content/weight differences in NMN medicines or health care products, resulting in inconsistent quality.
Innovation Solution
A method involving pH adjustment, vacuum concentration, solvent addition, and controlled cooling to convert NMN into a bulk structure, increasing its bulk density.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional crystal forms (anhydrous or dimethyl sulfoxide solvate) are used, then the NMN crystal structure is stable, but the bulk density remains low (0.2 g/ml) resulting in poor fluidity
Solution Approach 1:
The patent changes the physical and chemical parameters of the crystallization process, specifically using pH adjustment (to 4.5-6.5), controlled cooling rates (1-15°C/h), and specific solvent systems to transform the crystal morphology from rod-like to bulk structure, achieving bulk density of 0.52-0.71 g/ml while maintaining structural stability
Solution Approach 2:
The patent utilizes phase transition during controlled cooling crystallization, where the NMN solution transitions from liquid to solid crystal phase under specific temperature and pH conditions, forming bulk-shaped crystals with improved density and fluidity characteristics
2Ease of manufacture
If rod-like crystal structure is formed, then the crystallization process is simple, but the bulk density remains low leading to large content/weight difference in products
Solution Approach 1:
By adjusting pH to 4.5-6.5 and controlling cooling rate at 1-15°C/h, the patent transforms the crystal morphology from rod-like to bulk structure, which significantly improves bulk density and reduces content/weight variation in final products, thereby enhancing manufacturing precision without substantially complicating the process
3Quantity of substance
If poor solvent addition method is used, then bulk density increases to 0.52 g/ml, but the crystal structure becomes rod-like limiting further density improvement
Solution Approach 1:
The patent introduces pH adjustment (to 4.5-6.5) and controlled cooling rate (1-15°C/h) as additional parameters to the poor solvent addition method, which transforms the crystal shape from rod-like to bulk structure and further increases bulk density to 0.52-0.71 g/ml, overcoming the shape limitation of the conventional method
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly increases the bulk density of NMN crystals, doubling the particle size and improving production consistency, thereby addressing the issues of large content/weight differences and inconsistent quality.
Implementation Method 1
performing vacuum concentration or freeze drying on the aqueous solution of nicotinamide mononucleotide to obtain a semi-solid with a water content equal to or less than 15%
Implementation Method 2
performing vacuum concentration or freeze drying on the aqueous solution of nicotinamide mononucleotide to obtain a semi-solid with a water content equal to or less than 15%
Implementation Method 3
adding a solventing-out agent dropwise to the semi-solid under stirring
Implementation Method 4
performing cooling at a rate of 1-15° C./h to a crystallization end temperature of 5-18° C.
Implementation Method 5
after a crystal is completely precipitated, performing filtration and drying on the crystal to obtain a nicotinamide mononucleotide crystal with increased bulk density
Data Source
AI summary
The present disclosure provides a method for increasing the bulk density of a nicotinamide mononucleotide crystal and a crystal thereof. The method includes: dissolving nicotinamide mononucleotide in water to obtain an aqueous solution of nicotinamide mononucleotide; performing vacuum concentration or freeze drying on the aqueous solution of nicotinamide mononucleotide to obtain a semi-solid with a water content equal to or less than 15%; adding a solventing-out agent dropwise to the semi-solid under stirring, and meanwhile, performing cooling at a rate of 1-15° C./h to a crystallization end temperature of 5-18° C.; and after a crystal is completely precipitated, performing filtration and drying on the crystal to obtain a nicotinamide mononucleotide crystal with increased bulk density. An NMN crystal of a bulk structure can be prepared by the method, and compared with existing NMN crystals, the bulk density of the NMN crystal is doubled.